Duke Med News - Cancer patients who receive a drug that stimulates the growth of infection-fighting white blood cells may be significantly less likely to die from a chemotherapy-related complication characterized by fever and low white blood cell levels, according to a multi-institutional study led by researchers from the University of Rochester School of Medicine and Dentistry and the Duke Comprehensive Cancer Center.杜克大学医学新闻-癌症病人接受药物刺激增长的感染救火白血细胞，可明显减少可能死于化疗相关并发症，其特点是发烧及低白血球水平，根据一项多机构实验，由研究人员从美国罗切斯特大学医学院的牙医和杜克大学综合癌症中心。

“Chemotherapy drugs target cancer cells, but they can affect healthy cells as well, including infection-fighting white blood cells,” said Nicole M. Kuderer, M.D., a hematology-oncology fellow at Duke and lead author on the publication. "化疗药物靶癌细胞，但他们可以影响到健康的细胞，以及包括感染救火白血细胞中说： "妮可米kuderer ，海事处，血液肿瘤科研究员杜克，并导致作者对出版。 “When patients’ white blood cell counts drop too low, they are at risk for dangerous infections that can cause death.” "当病人的白血细胞计数下降得太低，他们正处于危险危险的感染可导致死亡" 。

Often, chemotherapy must be delayed, reduced in strength or halted when a patient’s white blood cell count is too low, potentially leading to poorer outcomes, she added.很多时候，化疗必须延迟，降低强度或停止时，病人的白血球过低，可能导致较差的结果，她补充说。

“Patients taking a drug known as granulocyte colony-stimulating factor early in their chemotherapy were about half as likely to develop dangerously low white blood cell counts with fever, and half as likely to die from infection,” Kuderer said. "病人服用药物称为粒细胞集落刺激因子早在化疗中，约有一半的可能发展的危险低白细胞计数发烧，另一半可能死于感染， " kuderer说。 “This study represents an important part of the effort to better treat this common complication in cancer patients receiving chemotherapy.” "这项研究是一个重要的努力的一部分，以更好地看待这个常见的并发症，在癌症病人接受化疗" 。

The researchers published their findings in the July 20, 2007 issue of the Journal of Clinical Oncology .研究人员将他们的发现公布在2007年7月20日发出的临床肿瘤学杂志 。 The work was part of research being conducted by the Awareness of Neutropenia in Chemotherapy (ANC) Study Group, a multi-institution, university-based network of investigators whose work is unrestrictedly funded by Amgen, the maker of a commonly utilized white blood cell booster that goes by the names Neupogen and Neulasta.这项工作是研究的一部分，现由意识的中性粒细胞在化疗（非国大）的研究小组，一个多机构，以大学为基础的网络的调查员，其工作是不受限制资安进公司，制造商普遍使用的白血细胞的助推器叫名字neupogen和neulasta 。 Kuderer also receives funding from the National Institutes of Health. kuderer也获得经费，由美国国家卫生研究院。

This study compiled the results of 17 trials involving more than 3,000 patients receiving chemotherapy of varying intensity to treat several different types of cancers.这项研究汇编结果17审理涉及超过3000个病人接受化疗强度不同对待几种不同类型的癌症。 The researchers found that nearly 40 percent of the patients who did not receive the white blood cell booster early in treatment developed the fever and low white blood cell levels called febrile neutropenia, compared to only 22 percent of the patients who took the drug in conjunction with their chemotherapy, Kuderer said.研究人员还发现，近40 ％的病人没有得到白血细胞助推器早期治疗发达发热及低白血球水平所谓发热嗜中性白血球减少，相比之下，只有22 ％的病人采取药物结合其化疗， kuderer说。

While white blood cell boosters were known to help patients receiving very intense doses of chemotherapy, this study showed that the drugs are also a benefit to cancer patients receiving more common chemotherapy doses, Kuderer said.而白血细胞的助推器众所周知，以帮助病人接受非常激烈剂量的化疗，这个研究结果显示，这个药物也有一个好处，为癌症病人接受更多的共同化疗剂量， kuderer说。

Recently revised American Society of Clinical Oncology (ASCO) and National Comprehensive Cancer Center Network (NCCN) guidelines for the use of drugs such as Neulasta and Neupogen align with the conclusions reached by this study.最近修订的美国临床肿瘤学协会（ asco ）和国家综合癌症中心网（ nccn ）使用准则的药物，如neulasta和neupogen配合所达成的各项结论这项研究。

“The new guidelines recommend using these types of drugs when at-risk patients begin chemotherapy, rather than waiting for complications to develop,” said Jeffrey Crawford, M.D., chief of the division of medical oncology at Duke and one of the study’s investigators. "新的指导方针建议用这些类型的药物时，处于危险状态的病人开始化疗，而不是等待并发症的发展， "杰弗里说，克劳福德，海事处，司司长肿瘤内科杜克大学和这项研究的一名调查员。 “The new recommendations also suggest that we need better methods to identify patients who are at higher risk of developing febrile neutropenia, and future studies will be aimed at doing just that.” "新的建议还认为，我们需要更好的方法，以确定病人是在风险较高的发展发热嗜中性白血球减少，而未来的研究将着眼于这样做。 "

White blood cell boosters can have side effects, including bone pain, which need to be reviewed and discussed with each patient being treated for cancer, Crawford said.白血细胞的助推器，可以有副作用，包括骨痛，需要检讨，并讨论了与每一个病人正在接受治疗的癌症，克劳福德说。